

GLP-1 / Obesity Research-Leader Map

A cited research-leadership and momentum snapshot built from current public PubMed records.

599

recent public records analyzed

10

ranked public research leaders

8

leading institutions surfaced

2025 to 2026

publication window

Decision use

This packet shows the work Tensorust can deliver for a portfolio team, corporate strategy group, or therapeutic-area owner: a traceable starting point for research diligence, expert mapping, and topic monitoring. It is a real source-limited analysis, not a product mockup.

What the public record helps surface	What this packet does not claim
- Which researchers and institutions repeatedly appear in the current record - Which subtopics dominate the retrieved literature - Where research activity is visible by year - Which records should be opened first	- Investment, clinical, or commercial conclusions - Citation-weighted influence or person identity resolution - Complete coverage of every paper, trial, or company - A substitute for clinical, legal, or investment diligence

Source and method


Query: **semaglutide OR tirzepatide OR GLP-1 receptor agonist obesity**. The packet analyzes 599 records published from 2025 through 2026 and retrieved from NLM PubMed. Every cited paper links to its PMID. Research leaders are ranked by recent publication volume in this retrieved set. Generated July 21, 2026.

Tensorust is built for cited, verifiable work from public data. Explore the live engine at tensorust-site.vercel.app.

Research momentum and leadership

Publication volume in the retrieved set is a discovery signal. It is not a measure of clinical authority, influence, or financial relevance.

Publication momentum



Top public research leaders

#	Researcher	Primary public affiliation	Papers
1	Wu Jheng-Yan	Chi Mei Medical Center	7
2	Rosenstock Julio	The University of Texas Southwestern Medical Center	5
3	Lin Yu-Min	Chi Mei Medical Center	4
4	Acosta Andres	Mayo Clinic	4
5	Mathieu Chantal	Clinical and Experimental Endocrinology	3
6	Frittitta Lucia	University of Catania	3
7	Sattar Naveed	University of Glasgow	3
8	Lee Keng-Wei	Chiali Tainan Taiwan.	3
9	Muscogiuri Giovanna	Dipartimento di Medicina Clinica e Chirurgia	3
10	Chi Kuan-Yu	Albert Einstein College of Medicine	3

Method note: The full paid workflow adds citation weighting, ORCID-led name disambiguation, trial-investigator mapping, competitor filters, and a buyer-defined source scope.

Institution and topic landscape

The tables below are public-record discovery signals that help a team decide where to investigate further.

Leading institutions	Active indexed subtopics
Mayo Clinic 17 records	Glucagon-Like Peptide-1 Receptor Agonists 66 records
Eli Lilly and Company 13 records	Semaglutide 56 records
Novo Nordisk A/S 11 records	Diabetes Mellitus, Type 2 53 records
University of California 10 records	Hypoglycemic Agents 49 records
University of Toronto 10 records	Obesity 47 records
Yale School of Medicine 8 records	Glucagon-Like Peptides 34 records
University of British Columbia 8 records	Tirzepatide 31 records
Novo Nordisk 7 records	

How this scales for a diligence team

Current delivery	Expansion path
Cited research landscapes, KOL and research-leader maps, Counterfactual claim-evidence briefs, public-source PDFs, and a live topic preview.	Cross-source landscapes joining publications with grants, patents, trials, contracts, company activity, supply risk, and recurring monitoring or alerts.

Cited audit trail

Representative recent public records from the same query set. Each title links directly to the underlying PubMed record.

Cited public record	Why it appears
Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes? PMID 42478869 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
GLP-1 Receptor Agonist and Bariatric Surgery Utilization Among Adolescents and Young Adults. PMID 42475086 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Affordable Semaglutide in India: Expanding Access and Unanswered Questions for Children and Special Populations. PMID 42474946 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder. PMID 42474323 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (T PMID 42473259 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Optimal Timing of GLP-1 Receptor Agonist Initiation in Patients with Obesity Eligible for Metabolic Bariatric Surgery. PMID 42471527 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Semaglutide promotes angiogenesis and blood-brain barrier repair after traumatic brain injury via PDGF-BB/PDGFRbeta/Ang1/Tie2/VEGF si PMID 42471364 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence. PMID 42470876 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use. PMID 42469146 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.

Limits and review standard

The source set is a recent PubMed retrieval, not a systematic review. Records may be incomplete, author names can collide, affiliations may be abbreviated, and publication counts are not citation-weighted. The analysis should be reviewed with the underlying sources before any investment, clinical, legal, regulatory, or partnership decision.

Prepared by Tensorust | cited, verifiable public-data intelligence